Jsc German Hospital

Tbilisi 0119

1 studies enrolling now · 2 studies all time

What they study most

MF, Myelofibrosis, NSCLC, Non-small Cell Lung Cancer, Post-ET Myelofibrosis, Post-PV MF, Primary Myelofibrosis

Studies at this site

• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer — Stopped early